A single therapy slows multiple cancers

Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

The single protein is HSP90, which acts as a to protect other proteins in the cell.

A team led by Ute Moll at the University of Göttingen in Germany found that blocking HSP90 activity rendered normally protected proteins vulnerable to attack and destruction. One of these proteins—called migration inhibitory factor—drives the growth of breast tumors. HSP90 inhibitors slowed the growth of MIF-expressing breast tumors in mice but had little effect on tumors lacking MIF.

HSP90 inhibitors also look promising for certain forms of leukemia, according to a study by David Weinstock and coworkers at the Dana-Farber Cancer Institute. They showed that HSP90 inhibitors slowed the growth of leukemias driven by hyperactive versions of the enzyme JAK2, many of which become resistant to JAK2-blocking drugs. The HSP90 inhibitors delayed the growth of resistant leukemia cells in mice.

Together these studies suggest that may represent a therapeutic target in many cancers.

More information: Schulz, R., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111117
Weigert, O., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111694

add to favorites email to friend print save as pdf

Related Stories

HSP90: New point of view on melanoma of the eye

Feb 19, 2008

Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize. This makes it a particularly challenging disease to fight, especially since chemotherapy is not very effective.

Sidestepping cancer's chaperone

Oct 18, 2007

Cancerous tumors are wildly unfavorable environments. Struggling for oxygen and nutrients while being bombarded by the body’s defense systems, tumor cells in fact require sophisticated adaptations to survive and grow. For ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.